Mauna Kea (ALMKT) | Financial Analysis & Statements
Mauna Kea Technologies S.A. Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Balance Sheet Metrics
Total Assets
16.2M
Total Liabilities
40.6M
Shareholders Equity
-24.4M
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2024
Mauna Kea Income Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 7.7M | 10.5M | 7.5M | 7.7M | 6.5M |
| Cost of Goods Sold | 1.2M | 2.1M | 2.0M | 2.0M | 2.1M |
| Gross Profit | 6.4M | 8.4M | 5.5M | 5.7M | 4.4M |
| Gross Margin % | 84.1% | 79.8% | 73.2% | 74.2% | 67.1% |
| Operating Expenses | |||||
| Research & Development | 3.6M | 3.9M | 4.1M | 3.3M | 3.2M |
| Selling, General & Administrative | 3.2M | 4.2M | 3.9M | 5.2M | 4.4M |
| Other Operating Expenses | 224.0K | 123.0K | 206.0K | 200.0K | 202.0K |
| Total Operating Expenses | 7.0M | 8.2M | 8.1M | 8.7M | 7.9M |
| Operating Income | -6.0M | -5.7M | -897.0K | -11.3M | -12.0M |
| Operating Margin % | -79.0% | -54.3% | -12.0% | -147.1% | -183.3% |
| Non-Operating Items | |||||
| Interest Income | 239.0K | 359.0K | 162.0K | 0 | 0 |
| Interest Expense | 457.0K | 270.0K | 254.0K | 27.0K | 49.0K |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | -10.4M | -3.3M | -11.2M | -13.4M | -12.8M |
| Income Tax | 0 | 475.0K | 0 | 0 | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -10.4M | -3.7M | -11.2M | -13.4M | -12.8M |
| Net Margin % | -135.9% | -35.6% | -149.5% | -174.6% | -196.0% |
| Key Metrics | |||||
| EBITDA | -8.0M | -1.5M | -9.9M | -11.2M | -11.4M |
| EPS (Basic) | €-0.16 | €-0.08 | €-0.25 | €-0.35 | €-0.42 |
| EPS (Diluted) | €-0.16 | €-0.08 | €-0.25 | €-0.35 | €-0.42 |
| Basic Shares Outstanding | 64072000 | 49302000 | 44515000 | 38082000 | 30527000 |
| Diluted Shares Outstanding | 64072000 | 49302000 | 44515000 | 38082000 | 30527000 |
Income Statement Trend
Mauna Kea Balance Sheet From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 1.9M | 7.9M | 3.1M | 11.9M | 8.6M |
| Short-term Investments | - | 36.0K | 9.0K | 29.0K | 58.0K |
| Accounts Receivable | 1.3M | 1.3M | 7.2M | 1.5M | 1.9M |
| Inventory | 4.3M | 2.9M | 3.2M | 3.0M | 2.7M |
| Other Current Assets | 4.0K | 8.0K | 6.0K | 8.0K | 10.0K |
| Total Current Assets | 9.0M | 14.3M | 15.1M | 18.7M | 14.5M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 10.9M | 10.2M | 10.7M | 10.3M | 10.0M |
| Goodwill | 1.5M | 2.0M | 2.7M | 3.4M | 3.1M |
| Intangible Assets | 1.5M | 2.0M | 2.7M | 3.4M | 3.1M |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | -1.0K | 1.0K | -1.0K | 1.0K | 1.0K |
| Total Non-Current Assets | 7.2M | 8.6M | 4.7M | 6.1M | 6.1M |
| Total Assets | 16.2M | 22.9M | 19.8M | 24.8M | 20.6M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.3M | 2.8M | 1.3M | 1.7M | 1.5M |
| Short-term Debt | 24.8M | 16.4M | 2.3M | 1.8M | 722.0K |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.8M | 1.7M | 1.6M | 2.2M | 3.0M |
| Total Current Liabilities | 33.4M | 26.7M | 12.7M | 7.3M | 6.3M |
| Non-Current Liabilities | |||||
| Long-term Debt | 7.2M | 13.4M | 26.9M | 26.9M | 26.2M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | 1.0K | 1.0K | 1.0K | - | - |
| Total Non-Current Liabilities | 7.3M | 13.5M | 27.1M | 27.7M | 26.4M |
| Total Liabilities | 40.6M | 40.2M | 39.7M | 35.1M | 32.7M |
| Equity | |||||
| Common Stock | 2.7M | 2.5M | 1.9M | 1.8M | 1.2M |
| Retained Earnings | -10.4M | -3.7M | -11.2M | -13.4M | -12.8M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -24.4M | -17.3M | -19.9M | -10.3M | -12.1M |
| Key Metrics | |||||
| Total Debt | 31.9M | 29.8M | 29.2M | 28.7M | 27.0M |
| Working Capital | -24.3M | -12.4M | 2.4M | 11.3M | 8.2M |
Balance Sheet Composition
Mauna Kea Cash Flow Statement From 2020 to 2024
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -10.4M | -3.7M | -11.2M | -13.4M | -12.8M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 549.0K | 113.0K | 327.0K | 561.0K | 616.0K |
| Working Capital Changes | -3.0M | 3.6M | -213.0K | -635.0K | 2.4M |
| Operating Cash Flow | -10.8M | 2.0M | -9.3M | -12.1M | -8.6M |
| Investing Activities | |||||
| Capital Expenditures | -214.0K | -369.0K | -141.0K | -1.1M | -1.1M |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -178.0K | -369.0K | -141.0K | -1.1M | -1.1M |
| Financing Activities | |||||
| Share Repurchases | - | - | - | - | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | - | - | - | 504.0K | 10.0M |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 1.4M | 6.7M | 890.0K | 15.5M | 8.4M |
| Free Cash Flow | -6.5M | -1.1M | -9.0M | -11.4M | -9.1M |
| Net Change in Cash | -9.6M | 8.3M | -8.5M | 2.3M | -1.3M |
Cash Flow Trend
Mauna Kea Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
-1.17
Forward P/E
-1.94
Price to Book
-1.37
Price to Sales
4.58
PEG Ratio
-1.94
Profitability Ratios
Profit Margin
-127.03%
Operating Margin
-69.26%
Return on Equity
42.66%
Return on Assets
-20.88%
Financial Health
Current Ratio
0.23
Debt to Equity
-1.35
Beta
0.99
Per Share Data
EPS (TTM)
€-0.36
Book Value per Share
€-0.37
Revenue per Share
€0.11
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| ALMKT | 37.4M | -1.17 | -1.37 | 42.66% | -127.03% | -1.35 |
| Eurobio Scientific | 229.6M | 108.64 | 1.33 | 2.24% | 2.90% | 0.19 |
| Median Technologies | 188.6M | -3.61 | - | 74.31% | -94.04% | -1.15 |
| Guerbet S.A | 127.3M | 13.77 | 0.47 | -34.58% | -13.56% | 169.65 |
| Affluent Medical | 122.2M | -8.37 | 5.24 | -62.51% | -279.97% | 110.96 |
| Diagnostic Medical | 34.5M | -133.50 | 2.16 | -11.62% | -3.37% | 138.72 |
Financial data is updated regularly. All figures are in the company's reporting currency.